🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsed or Refractory Peripheral T-cell Lymphoma

Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma NCT06160843Phase 21 site📍 Singapore National Cancer Centre, Singapore · Tests: Pembrolizumab IV infusion Q3W, with daily oral Olaparib. Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma NCT07502768Phase 1, Phase 21 site📍 Shanghai Rong Tao · Tests: Tislelizumab, Zeprumetostat A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype NCT06522737Phase 344 sites📍 Ghent📍 Leuven📍 Prague SecuraBio · Tests: Duvelisib, Gemcitabine, Bendamustine Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells NCT06420076Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: CD5/CD7 CAR-T RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies NCT06732492Phase 11 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: RD13-02 cell infusion Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50) NCT06733051Phase 22 sites📍 Beijing📍 Guangzhou Sun Yat-sen University · Tests: Golidocitinib, Benmelstobart Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma NCT06934382Phase 11 site📍 Philadelphia Stephan Grupp MD PhD · Tests: Allogeneic anti-CD7 CAR-T cells (BEAM-201) A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL NCT06966154Phase 1, Phase 21 site📍 Shanghai Fudan University · Tests: tislezumab, golidocitinib, Selinexor Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma NCT06793956Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Sintilimab and Linperlisib Combination Treatment Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual… Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) NCT06810778Phase 1, Phase 21 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Duvelisib, Venetoclax Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology NCT06378190Phase 1, Phase 28 sites📍 Barcelona📍 L'Hospitalet de Llobregat📍 Madrid Instituto de Investigación Biomédica de Salamanca · Tests: CAR-T cells therapy To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL NCT07143929Phase 11 site📍 Beijing Peking University People's Hospital · Tests: CAR-T Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL NCT06874946Phase 1, Phase 21 site📍 Beijing Peking University People's Hospital · Tests: CD5-targeted CAR-T cells Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma NCT06561048Phase 337 sites📍 Duarte📍 Irvine📍 San Francisco Corvus Pharmaceuticals, Inc. · Tests: Soquelitinib, Belinostat, Pralatrexate A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL NCT06854653Phase 215 sites📍 Duarte📍 Irvine📍 New Haven Prescient Therapeutics, Ltd. · Tests: PTX-100 Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma NCT05996185Phase 22 sites📍 New Haven📍 New York Yale University · Tests: Mogamulizumab, DA-EPOCH Protocol, CHOEP protocol Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT NCT06839456Phase 1, Phase 21 site📍 Philadelphia Children's Hospital of Philadelphia · Tests: Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3, Phase 2 Maximum Tolerated Dose determined in Phase 1,… Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas NCT06176690Phase 12 sites📍 Houston📍 Houston Baylor College of Medicine · Tests: C7R.CD30.CAR-EBVST cells A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas NCT07018752Phase 1, Phase 220 sites📍 Caen📍 Clermont-Ferrand📍 Créteil The Lymphoma Academic Research Organisation · Tests: roginolisib, golcadomide, azacitidine Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma NCT07093710Phase 1, Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Golidocitinib, Mitoxantrone Hydrochloride Liposome, Chidamide A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma NCT06776952Phase 31 site📍 Beijing Evopoint Biosciences Inc. · Tests: XNW5004 ; Chidamide placebo, XNW5004 placebo; Chidamide CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas NCT06925464Phase 1, Phase 24 sites📍 Beijing📍 Zhanjiang📍 Shanghai Beijing GoBroad Hospital · Tests: CD7 CAR-T cells infusion GVM±R in Patients With Relapsed or Refractory Aggressive NHL. NCT06244368Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: GVM±R regimen CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas NCT07022964Phase 1, Phase 23 sites📍 Beijing📍 Shanghai📍 Shanghai Beijing GoBroad Hospital · Tests: CD5 CAR-T cells infusion Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL) NCT05833724Phase 26 sites📍 Kaohsiung City📍 Kaohsiung City📍 New Taipei City Great Novel Therapeutics Biotech & Medicals Corporation · Tests: Chidamide Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL NCT04747236Phase 26 sites📍 Long Beach📍 New Haven📍 New York University of Virginia · Tests: Azacytidine, Romidepsin, Belinostat, Pralatrexate, Gemcitabine Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma NCT06508463Phase 12 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma NCT06376721Phase 1, Phase 21 site📍 Beijing Beijing Tongren Hospital · Tests: Linperlisib, Camrelizumab, Pegaspargase, Dexamethasone Evaluate the Safety and Clinical Activity of HH2853 NCT04390737Phase 1, Phase 225 sites📍 Phoenix📍 Jacksonville📍 Rochester Haihe Biopharma Co., Ltd. · Tests: HH2853 Tablets
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy